Skip to content
Home/Companies/Pharma/Prolevi Bio

Prolevi Bio

Pharma·Sweden·Active·4yr hold
Entry
2022
Hold
4yr
Status
Active

Who owns Prolevi Bio?

Prolevi Bio is a Swedish Pharma company, currently owned by Almi Invest since 2022.

Hand-verified · updated 2026-08-18

Open JSON · CC-BY
Almi Invest
Investor
Almi Invest
Almi Invest (Regional funds) · 2009 · VC

Key facts

HQSweden
SectorPharma
StatusActive

More from Almi Invest (Regional funds)

Other portfolio companies in the same fund.

Cellevate
Active
BiotechSweden· 2026
CubaseBio
Active
BiotechSweden· 2026
DAJE Prevent
Active
MedTechSweden· 2026
Permitify
Active
SaaSSweden· 2026
Radar Reticence
Active
SoftwareSweden· 2026
Rivus
Active
SoftwareSweden· 2026

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Abacus Pharmaceuticals
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
AdipoPharma
AdipoPharma
Active
Capital Grand EstFrance
Advantice Health
Advantice Health
Active
TA AssociatesUS
Alcala Farma
Active
Advent InternationalSpain
Alvogen
Alvogen
Active
CVC Capital Partners
Anovo
Anovo
Active
ArdianUS

Questions

Who owns Prolevi Bio?

Prolevi Bio is currently owned by Almi Invest, through Almi Invest (Regional funds), since 2022.

When did Almi Invest acquire Prolevi Bio?

Almi Invest acquired Prolevi Bio in 2022.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue